Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a higher stem cell dose beat back lymphoma?

NCT ID NCT02570542

Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether giving more stem cells during an autologous transplant helps people with relapsed or refractory diffuse large B-cell lymphoma recover better and stay cancer-free longer. About 59 adults who have already tried one chemotherapy will get high-dose chemo (BEAM) followed by a stem cell infusion. Researchers will compare different stem cell doses to see which leads to better immune recovery and longer time without the cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stem cells (CD34+ cells) collected after plerixafor mobilization, followed by BEAM chemotherapy
What this could lead to
If successful, this could help doctors choose the best stem cell dose to improve recovery and delay lymphoma progression after transplant.
What could go wrong
This is a small, early-phase study with only 59 participants, so results may not apply to all patients. The transplant itself carries risks like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

59 people

The number who actually took part.

Started

Oct 2015

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old * Diagnosed with relapsed or refractory de novo DLBCL or follicular lymphoma transformed to DLBCL to one previous line of anthracycline-containing chemotherapy * KPS ≥ 70 * Complete or partial response by IWG Working Group or ICML Criteria to maximum of one salvage line of chemotherapy without pre-HDT/ASCT salvage radiotherapy. * Eligible for high-dose therapy and autologous stem-cell rescue * Serum creatinine ≤ 1.5 mg/dL, or if creatinine \>1.5 mg/dL, calculated creatinine clearance of ≥50 mL/min by 24 hour creatinine clearance or CKD-EPI. * Last cycle of most recent salvage therapy within 8 weeks of enrollment * Total bilirubin \< 2.0 mg/dL o If Gilbert"s disease is suspected and total bilirubin \> 2.0 mg/dL, direct bilirubin must be \< 2.0 mg/dL * Females of childbearing potential and males must agree to use an acceptable form of contraception per institutional practices. Exclusion Criteria: * Disease progression by IWG Working Group or ICML Criteria since last therapy * Prior autologous or allogeneic stem cell transplantation * HIV infection * Comorbid condition(s) which, in the opinion of the attending physician and/or MSKCC Principal Investigator, will preclude stem cell mobilization and/or high-dose therapy with autologous stem cell rescue * Treatment plan that includes post-transplant maintenance therapy * Salvage therapy that includes involved field radiotherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B cell lymphoma (DLBCL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diffuse large B cell lymphoma (DLBCL) Refractory diffuse large B-cell lymphoma (DLBCL) Relapsed diffuse large B-cell lymphoma (DLBCL)

Contacts and locations

Locations

  • Columbia University

    New York, New York, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up Only)

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Bergen (Consent and Follow Up Only)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack (Consent and Follow-up Only)

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth (Consent and Follow up Only)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (Consent and Follow up Only)

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

  • Northwell Health (Data collection only)

    Manhasset, New York, 11030, United States

  • Tennessee Oncology

    Nashville, Tennessee, 37203, United States

  • Texas Transplant Institute

    San Antonio, Texas, 78229, United States

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198-7680, United States

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.